NCT04807270

Brief Summary

The aim of our study is to determine the effects of intra-articular Platelet-Rich Plasma (PRP) prepared with two different techniques on pain intensity, functional status, quality of life, functional balance and femoral cartilage thickness in patients with knee osteoarthritis.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
96

participants targeted

Target at P50-P75 for not_applicable knee-osteoarthritis

Timeline
Completed

Started May 2021

Typical duration for not_applicable knee-osteoarthritis

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

March 17, 2021

Completed
2 days until next milestone

First Posted

Study publicly available on registry

March 19, 2021

Completed
2 months until next milestone

Study Start

First participant enrolled

May 20, 2021

Completed
1.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 20, 2022

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2023

Completed
Last Updated

May 22, 2026

Status Verified

March 1, 2023

Enrollment Period

1.5 years

First QC Date

March 17, 2021

Last Update Submit

May 19, 2026

Conditions

Keywords

knee osteoarthritisplatelet rich plasma

Outcome Measures

Primary Outcomes (1)

  • Change from baseline activity pain score at 1-months, 3-months and 6-months

    Visual Analogue Scale-Activity pain (0-10 point). Higher scores mean a worse outcome

    Baseline, 1-month, 3-month, 6-month

Secondary Outcomes (5)

  • Change from baseline activity pain score at 1-months, 3-months and 6-months

    Baseline, 1-month, 3-month, 6-month

  • Change from baseline pain, stiffness and physical function at 1-months, 3-months and 6-months

    Baseline, 1-month, 3-month, 6-month

  • Change from baseline quality of life and global assessment at 1-months, 3-months and 6-months

    Baseline, 1-month, 3-month, 6-month

  • Change from baseline functional balance at 3-months and 6-months

    Baseline, 3-month, 6-month

  • Change from baseline femoral cartilage thickness measurement by ultrasound at 6 months

    Baseline, 6-month

Study Arms (3)

T-LAB / NEXT PRP SYRINGE

ACTIVE COMPARATOR

In the first group (PRP1 group; non-anticoagulant pure PRP), prepared with Next PRP Syringe in 3 sessions will be applied.

Other: Intra-articular T-LAB / Next PRP Syringe

T-LAB / PRP KIT

ACTIVE COMPARATOR

In the second group (PRP2 group; amber PRP) prepared with T-LAB / PRP KIT in 3 sessions will be applied.

Other: Intra-articular T-LAB / PRP KIT injection

SALINE

SHAM COMPARATOR

In the third group (saline group), prepared with SALINE in 3 sessions will be applied.

Other: Intra-articular SALINE injection

Interventions

PRP containing anticoagulant will be prepared using T-LAB / PRP KIT. 4 ml of PRP will be injected intra-articularly three times at 2-week intervals. As a home exercise program, hamstring and quadriceps stretching, quadriceps isometric strengthening, and short arc terminal extension exercises will be given at least three days a week with 3 sets of 10 repetitions.

T-LAB / PRP KIT

Similar to the PRP protocol, 4 mL of 0.9% sodium chloride will be injected intra-articularly. As a home exercise program, hamstring and quadriceps stretching, quadriceps isometric strengthening, and short arc terminal extension exercises will be given at least three days a week with 3 sets of 10 repetitions.

SALINE

Anticoagulant-free pure PRP will be prepared using T-LAB / Next PRP Syringe. 4 ml of PRP will be injected intra-articularly three times at 2-week intervals. As a home exercise program, hamstring and quadriceps stretching, quadriceps isometric strengthening, and short arc terminal extension exercises will be given at least three days a week with 3 sets of 10 repetitions.

T-LAB / NEXT PRP SYRINGE

Eligibility Criteria

Age30 Years - 75 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients with chronic symptomatic knee pain between the ages of 30 and 75 years
  • Presence of Kellgren-Lawrence stage 2-3 osteoarthritis on current anterior-posterior knee radiographs
  • The ability to walk independently

You may not qualify if:

  • Previous treatment with an autologous blood product or stem cell preparation
  • Severe knee effusion
  • Concomitant severe meniscus or ligament injury
  • Recent cancer or other tumors
  • History of knee surgery
  • Previous diagnosis of a neuromuscular, infectious, or inflammatory disease
  • Bleeding disorders and/or use of warfarin
  • Body mass index above 40 kg/m²
  • Cardiac or systemic diseases that could affect participation in the exercise program

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Istanbul University Istanbul Faculty of Medicine, Department of Physical Medicine and Rehabilitation

Istanbul, Fatıh, 34034, Turkey (Türkiye)

Location

MeSH Terms

Conditions

Osteoarthritis, Knee

Interventions

Sodium Chloride

Condition Hierarchy (Ancestors)

OsteoarthritisArthritisJoint DiseasesMusculoskeletal DiseasesRheumatic Diseases

Intervention Hierarchy (Ancestors)

ChloridesHydrochloric AcidChlorine CompoundsInorganic ChemicalsSodium Compounds

Study Officials

  • Demirhan Diracoglu, Prof.

    Istanbul University Istanbul Faculty of Medicine, Department of Physical Medicine and Rehabilitation

    STUDY DIRECTOR
  • Ekin I Sen, Asst. Prof.

    Istanbul University Istanbul Faculty of Medicine, Department of Physical Medicine and Rehabilitation

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
MD, Sub-Investigator

Study Record Dates

First Submitted

March 17, 2021

First Posted

March 19, 2021

Study Start

May 20, 2021

Primary Completion

November 20, 2022

Study Completion

January 1, 2023

Last Updated

May 22, 2026

Record last verified: 2023-03

Locations